title: [Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer].
abstract: BACKGROUND
  Epidermal growth factor receptor tyrosine kinase inhinitors (EGFR-TKIs) inhibit tumor growth by affecting signal transduction, and are well tolerated. The aims of this study was to observe the effect of erlotinib in patients with squamous cell lung cancer.
  
  
  METHODS
  The 34 patients with squamous cell lung cancer treated with erlotinib 150 mg orally once daily until disease progression or intolerable adverse reactions.
  
  
  RESULTS
  The 7 patients were treated with erlotinib as first-line treatment, 6 patients as maintenance therapy (1 case withdrawal of severe toxicity), 9 patients second-line treatment, 5 patients as third-line and 7 patients as further-line therapy. 11 patients died. The median progression-free survival (PFS) was 3.5 months, ranging from 1 month to 55 months (the patient withdrawal of severe toxicity was not included).
  
  
  CONCLUSIONS
  Erlotinib was effective for patients with squamous cell lung cancer who can not tolerate chemotherapy or refused chemotherapy and with unknown EGFR status. Adverse reactions were tolerable.
authors.affiliation: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;Beijing Chaoyang Sanhuan Cancer Hospital, Beijing 100122, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Cheng
authors.affiliation: Beijing Chaoyang Sanhuan Cancer Hospital, Beijing 100122, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.affiliation: Beijing Chaoyang Sanhuan Cancer Hospital, Beijing 100122, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Chen
authors.affiliation: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
authors.forename: Puyuan
authors.initials: P
authors.lastname: Xing
authors.affiliation: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
authors.forename: Junling
authors.initials: J
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D000069347:Erlotinib Hydrochloride / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging
chemical_list: D000970:Antineoplastic Agents; D000069347:Erlotinib Hydrochloride